76
|
Pointreau Y, Lafond C, Legouté F, Trémolières P, Servagi-Vernat S, Giraud P, Maingon P, Calais G, Lapeyre M. Radiothérapie des cancers du larynx. Cancer Radiother 2016; 20 Suppl:S131-5. [DOI: 10.1016/j.canrad.2016.07.018] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
77
|
Peyraga G, Lafond C, Pointreau Y, Giraud P, Maingon P. [Nasal cavity and paranasal sinus cancer]. Cancer Radiother 2016; 20 Suppl:S99-S103. [PMID: 27528562 DOI: 10.1016/j.canrad.2016.07.035] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The nasal cavity and parasinusal cancer are rare (10% of tumors of the head and neck) and are mainly represented by squamous cell carcinoma of the nasal cavity or the maxillary sinus and adenocarcinoma of the ethmoid sinus (occupational disease, wood dust). The most common clinical sign is nasal obstruction, but tumors can also manifest as rhinorrhea and/or epistaxis (usually unilateral signs). A magnetic resonance imaging of the facial structure is systematic for staging before treatment. The treatment consists of a first surgery if the patient is operable with a resectable tumor. If it is not the case, the treatment consists of radiotherapy (RT) associated with chemotherapy (CT) according to the initial data (T3/T4 or N+). After first surgery, RT is indicated (except T1N0 with complete resection) associated with a CT based on postoperative data (capsular effraction or incomplete resection). Lymph node irradiation is considered case by case, but is indicated in any nodal involvement. RT must be an intensity modulated RT (IMRT), static or dynamic, and must be imagery guided (IGRT). According to ICRU 83, doses to organs at risk and target volumes must be carried. Finally, after a post-treatment baseline imaging between 2 and 4 months, monitoring will be alternated with the ENT surgeon every 2 or 3 months for 2 years, then every 4 to 6 months for 5 years.
Collapse
MESH Headings
- Adenocarcinoma/diagnosis
- Adenocarcinoma/diagnostic imaging
- Adenocarcinoma/radiotherapy
- Adenocarcinoma/therapy
- Aftercare
- Carcinoma, Squamous Cell/diagnosis
- Carcinoma, Squamous Cell/diagnostic imaging
- Carcinoma, Squamous Cell/radiotherapy
- Carcinoma, Squamous Cell/therapy
- Combined Modality Therapy
- Dose Fractionation, Radiation
- Humans
- Lymphatic Irradiation
- Maxillary Sinus Neoplasms/radiotherapy
- Nasal Cavity
- Nose Neoplasms/diagnosis
- Nose Neoplasms/diagnostic imaging
- Nose Neoplasms/radiotherapy
- Nose Neoplasms/therapy
- Organs at Risk
- Paranasal Sinus Neoplasms/diagnosis
- Paranasal Sinus Neoplasms/diagnostic imaging
- Paranasal Sinus Neoplasms/radiotherapy
- Paranasal Sinus Neoplasms/therapy
- Radiation Injuries/etiology
- Radiation Injuries/prevention & control
- Radiotherapy Dosage
- Radiotherapy Planning, Computer-Assisted
- Radiotherapy, Adjuvant/methods
- Radiotherapy, Adjuvant/standards
- Radiotherapy, Image-Guided
- Radiotherapy, Intensity-Modulated/adverse effects
- Radiotherapy, Intensity-Modulated/methods
- Radiotherapy, Intensity-Modulated/standards
Collapse
|
78
|
Mirjolet C, Merlin JL, Dalban C, Maingon P, Azria D. Correlation between radio-induced lymphocyte apoptosis measurements obtained from two French centres. Cancer Radiother 2016; 20:391-4. [PMID: 27372557 DOI: 10.1016/j.canrad.2016.03.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Revised: 03/07/2016] [Accepted: 03/09/2016] [Indexed: 11/30/2022]
Abstract
PURPOSE OF THE RESEARCH In the era of modern treatment delivery, increasing the dose delivered to the target to improve local control might be modulated by the patient's intrinsic radio-sensitivity. A predictive assay based on radio-induced lymphocyte apoptosis quantification highlighted the significant correlation between CD4 and CD8 T-lymphocyte apoptosis and grade 2 or 3 radiation-induced late toxicities. By conducting this assay at several technical platforms, the aim of this study was to demonstrate that radio-induced lymphocyte apoptosis values obtained from two different platforms were comparable. MATERIALS AND METHODS For 25 patients included in the PARATOXOR trial running in Dijon the radio-induced lymphocyte apoptosis results obtained from the laboratory of Montpellier (IRCM, Inserm U1194, France), considered as the reference (referred to as Lab 1), were compared with those from the laboratory located at the Institut de cancérologie de Lorraine (ICL, France), referred to as Lab 2. Different statistical methods were used to measure the agreement between the radio-induced lymphocyte apoptosis data from the two laboratories (quantitative data). The Bland-Altman plot was used to identify potential bias. RESULTS All statistical tests demonstrated good agreement between radio-induced lymphocyte apoptosis values obtained from both sites and no major bias was identified. CONCLUSIONS Since radio-induced lymphocyte apoptosis values, which predict tolerance to radiotherapy, could be assessed by two laboratories and showed a high level of robustness and consistency, we can suggest that this assay be extended to any laboratories that use the same technique.
Collapse
|
79
|
Rouanet P, Rullier E, Lelong B, Maingon P, Tuech Jean J, Pezet D, Rivoire M, Meunier B, Nougaret S, Castan F, Lemanski C, Gourgou S, Ychou M. O-021 Tailored strategy for locally-advanced rectal carcinoma: preliminary results of a phase II multicenter trial (GRECCAR 4). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw198.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
80
|
Truc G, Bernier V, Mirjolet C, Dalban C, Mazoyer F, Bonnetain F, Blanchard N, Lagneau É, Maingon P, Noël G. A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma. Cancer Radiother 2016; 20:193-8. [PMID: 27117900 DOI: 10.1016/j.canrad.2015.12.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2015] [Revised: 10/02/2015] [Accepted: 12/10/2015] [Indexed: 10/21/2022]
Abstract
PURPOSE To evaluate the maximum tolerated dose of simultaneous integrated-boost intensity-modulated radiotherapy (SIB-IMRT) associated with temozolomide in patients with glioblastoma. PATIENTS AND METHODS Between November 2009 and January 2012, nine patients with malignant glioma were enrolled in this phase I clinical trial. Radiotherapy was delivered using fractions of 2.5Gy on the planning target volume b and of 1.9Gy on the planning target volume a. Volumes were defined as follow: gross tumour volume b: tumour taking up contrast on T1 weighted MRI images; clinical target volume b: gross tumour volume b+0.5cm (adapted to the anatomical structures) and lastly planning target volume b: clinical target volume b+0.5cm; gross tumour volume a: tumour (gross tumour volume b)+2cm and including oedema outlined on T2Flair MRI sequences; clinical target volume a gross tumour volume a+0.5cm (adapted to the anatomical structures); planning target volume a: clinical target volume a+0.5cm. Three patients were enrolled at each of the three levels of dose (70, 75 and 80Gy prescribed on the planning target volume b and 56, 60 and 60.8Gy on the planning target volume a). Radiotherapy was delivered with temozolomide according to the standard protocol. Dose-limiting toxicities were defined as any haematological toxicities at least grade 4 or as any radiotherapy-related non-haematological acute toxicities at least grade 3, according to the Common Terminology Criteria for Adverse Events, version 3.0. RESULTS Until the last dose level of 80Gy, no patient showed dose-limiting toxicity. CONCLUSIONS SIB-IMRT, at least until a dose of 80Gy in 32 daily fractions, associated with temozolomide is feasible and well tolerated.
Collapse
|
81
|
Thouant M, Bertaut A, Pommier P, Maingon P, Martin E, Quivrin M, Vulquin N, Ladoire S, Cormier L, Carrie C, Crehange G. Which PSA Endpoint Best Predicts Disease-Free Survival in Prostate Cancer Patients Treated With Exclusive Radiation Therapy Combined With Hormones? Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
82
|
Mirjolet C, Charon-barra C, Arbez-gindre F, Gauthier M, Maingon P, Barthod Z, Leroux A, Merlin J, Peiffert D, Dalban C, Ladoire S, Bosset J, Crehange G. 2009 Tumoral lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer as a prognostic factor for survival: The LYMPHOREC study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30934-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
83
|
Vrieling C, Van Werkhoven E, Poortmans P, Struikmans H, Weltens C, Fourquet A, Jager J, Schinagl D, Collette L, Maingon P, Bartelink H. 1BA The impact of pathological factors on long-term local control in the EORTC boost no-boost trial. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(15)30067-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
84
|
Jean-Mary E, Dalban C, Serre A, Maingon P, Petitfils A, Mirjolet C, Vulquin N, Wiazzane N, Crehange G. 2069 Elective nodal irradiation during exclusive chemoradiation for locally-advanced esophageal cancer: IMRT better spares critical organs at risk. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30992-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
85
|
Borg C, André T, Mantion G, Boudghène F, Mornex F, Maingon P, Adenis A, Azria D, Piutti M, Morsli O, Bosset J. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study. Ann Oncol 2014; 25:2205-2210. [DOI: 10.1093/annonc/mdu377] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
86
|
Bolla M, Maingon P, Van Den Bergh A, Carrie C, Villa S, Kitsios P, Poortmans P, Sundar S, Van Der Steen-Banasik E, Collette L. 02 Results of EORTC 22991: 3D-CRT/IMRT with or without 6-month androgen deprivation therapy in localized T1b-cT2aN0M0 prostate cancer (EORTC 22991). ACTA ACUST UNITED AC 2014. [DOI: 10.1016/s1569-9056(14)61223-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
87
|
Mirjolet C, Dalban C, Gauthier M, Walker P, Martin E, Truc G, Peignaux-Casasnovas K, Naudy S, Maingon P, Créhange G. Cancer de la prostate localisé et radiothérapie conformationnelle avec modulation d’intensité : quels sont les paramètres dosimétriques les plus pertinents pour prédire la toxicité digestive aiguë ? Cancer Radiother 2014. [DOI: 10.1016/j.canrad.2014.07.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
88
|
Jean-Mary E, Dalban C, Serre A, Maingon P, Petitfils A, Mirjolet C, Vulquin N, Wiazzane N, Créhange G. Chimioradiothérapie exclusive ganglionnaire prophylactique chez les patients traités dans les cancers de l’œsophage localement évolués : la radiothérapie avec modulation d’intensité épargne mieux les organes à risque. Cancer Radiother 2014. [DOI: 10.1016/j.canrad.2014.07.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
89
|
Vulquin N, Feutray S, Peignaux-Casasnovas K, Humbert O, Créhange G, Truc G, Maingon P, Martin É. Évaluation radiologique de la réponse tumorale après radiothérapie pulmonaire en conditions stéréotaxiques. Cancer Radiother 2014; 18:414-9. [DOI: 10.1016/j.canrad.2014.07.157] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2014] [Accepted: 07/24/2014] [Indexed: 12/25/2022]
|
90
|
Maingon P, Lisbona A. [Irradiation in stereotactic conditions: prerequisites]. Cancer Radiother 2014; 18:383-6. [PMID: 25179251 DOI: 10.1016/j.canrad.2014.06.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2014] [Accepted: 06/20/2014] [Indexed: 12/31/2022]
Abstract
Indications of treatment by stereotactic body radiotherapy are dramatically increasing due to new potential indications. The conditions associated with the treatment delivery are multiple. The first step of the process is crucial. It is related to the validation of the indication proposed during the multidisciplinary meeting as regard the evidence-based proof of the concept. These emerging techniques mainly extracranial stereotactic body irradiation do not benefit from long-term evaluation in terms of efficiency as well as normal tissue late toxicities. Priority should be given to prospective independent clinical trials, validated by an independent scientific committee, performed under a relevant and well dedicated multicentric quality assurance program aiming to improve knowledge and selection of indications. The SFRO is still working with others professionals on the definition of the conditions for the implementation of such treatments and actively collaborates with the authorities to define the appropriate conditions to preserve the quality of the treatment delivery under these specific conditions.
Collapse
|
91
|
Quivrin M, Loffroy R, Mirjolet C, Cueff A, Sottier D, Bidault F, Martin E, Maingon P, Walker P, Crehange G. Postimplant Multiparametric MRI-Based Dosimetry After Permanent Iodine Seed Prostate Brachytherapy: The Impact of the Dose Delivered to the Dominant Intraprostatic Lesion on Prostate-Specific Antigen Bounce. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
92
|
Struikmans H, Collette S, Van den Bogaert W, Kirkove C, Budach V, Maingon P, Valli M, Fourquet A, Bartelink H, Poortmans P. 6LBA The benefit of regional irradiation in stage I–III breast cancer: 10 years results of the EORTC ROG and BCG phase III trial 22922/10925. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70114-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
93
|
Maingon P. 126: The Radiation Oncology Group of EORTC: From the past to the future. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)34147-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
94
|
Järvinen H, Bly R, Malicki J, Jahnen A, Godet J, Valero M, Prieto C, Krengli M, Maingon P. SP-0329: ACCIRAD: European guidelines on risk assesment in radiotherapy - results of expert consensus and final version. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30434-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
95
|
Poortmans P, Struikmans H, Collette S, Kirkove C, Budach V, Maingon P, Valli M, Fourquet A, Van den Bogaert W, Bartelink H. OC-0523: Lymph node RT improves survival in breast cancer: 10 years results of the EORTC ROG and BCG phase III trial 22922/10925. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30629-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
96
|
Soltys B, Dalban C, Mirjolet C, Wiazzane N, Serre AA, Zanetta S, Thiebaut S, Maingon P. Comparaison des réirradiations conformationnelles avec modulation d’intensité des carcinomes de la tête et du cou selon le schéma de Vokes et le schéma monofractionné. Cancer Radiother 2013. [DOI: 10.1016/j.canrad.2013.06.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
97
|
Soltys B, Wiazzane N, Mirjolet C, Dalban C, Serre AA, Zanetta S, Thiebaut S, Créhange G, Maingon P. [Reirradiations of head and neck cancers: state of the concept and ways of development]. Cancer Radiother 2013; 17:508-12. [PMID: 23999251 DOI: 10.1016/j.canrad.2013.07.142] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2013] [Accepted: 07/12/2013] [Indexed: 11/28/2022]
Abstract
The treatment of local recurrence or second primary developed in irradiated area in the field of head and neck carcinoma, should be planned and organized through multidisciplinary discussions. The outcome of such a clinical situations benefits from second line and advanced technology treatments. Only a few patients are amenable to salvage surgery, hence radiation therapy, combined or not with chemotherapy, takes a major role in these indications. This overview of the literature describes recent development in this field, aiming to improve local control while the sparing of organ at risk remains an important goal. Radiation therapy is currently implementing major new technologies set to improve external beam irradiation with new concepts on dose, fractionation, intensity modulated radiation therapy and stereotactic approach - as well as in brachytherapy. Apart from dedicated studies, the great heterogeneity of the treated patients should be underlined and taken into consideration. However, current data confirm the feasibility of reirradiation with acceptable local control and toxicity.
Collapse
|
98
|
Chauvet B, Mahé MA, Maingon P, Mazeron JJ, Mornex F. Livre blanc de la radiothérapie en France 2013. Douze objectifs pour améliorer un des traitements majeurs du cancer. Cancer Radiother 2013; 17 Suppl 1:S2-72. [DOI: 10.1016/j.canrad.2013.04.002] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
99
|
Malicki J, Jarvinen H, Godet J, Skrobala A, Valero M, Jahnen A, Przybylska K, Maingon P, Krengli M, Bly R. SU-C-137-06: What Was the Impact Of European Medical Exposure Directive On Regulation On Clinical Practice Associated with Accidental Exposures, Reporting and Risk Analyses in Radiotherapy? Med Phys 2013. [DOI: 10.1118/1.4813937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
100
|
Dabakuyo T, Arnaud A, Maingon P, Causeret S, Coudert B, Fumoleau P, Arnould L, Poillot ML, Arveux P, Crehange G, Bonnetain F. Impact of neoadjuvant chemotherapy on survival in breast cancer patients in daily practice: a population-based study. Eur J Cancer Care (Engl) 2013; 22:638-47. [DOI: 10.1111/ecc.12069] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/02/2013] [Indexed: 11/26/2022]
|